Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
•Journal Article
Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
L Opstaele,Rob Bielen,Suzanne Bourgeois,Christophe Moreno,Frederik Nevens,Geert Robaeys,H. Van Vlierberghe +6 more
TL;DR: A broad screening strategy combined with treatment is likely to be a cost-effective strategy to detect and treat HCV infected patients and diminish the HCV burden in Belgium.
10
Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.
Stijn Van Hees,Heng Chi,Bettina E. Hansen,Bettina E. Hansen,Suzanne Bourgeois,Hans Van Vlierberghe,Thomas Sersté,Sven Francque,David Wong,Dirk Sprengers,Christophe Moreno,Frederik Nevens,Harry L.A. Janssen,Harry L.A. Janssen,Thomas Vanwolleghem,Thomas Vanwolleghem +15 more
TL;DR: Off-treatment Hepatitis B surface antigen (HBsAg) loss was investigated in a multicentric, international observational cohort of patients with Nucleos(t)ide Analogue induced HBeAg seroconversion and persistent viral control after treatment cessation following NA induced H beAg serconversion was associated with high HBsAg loss rates in Caucasian patients.
The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience
Rob Bielen,Christophe Moreno,H. Van Vlierberghe,Suzanne Bourgeois,Jean-Pierre Mulkay,Sven Francque,Wim Verlinden,C Brixko,J Decaestecker,C de Galocsy,F Janssens,Mike Cool,C. Van Steenkiste,F D'Heygere,K. Wuyckens,Frederik Nevens,Geert Robaeys +16 more
9
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Philippe J. Zamor,Ashley Brown,Douglas E. Dylla,John F. Dillon,Anne F Luetkemeyer,Jordan J. Feld,David Mutimer,Reem Ghalib,Eric Crown,Sandra S. Lovell,Yiran Hu,Christophe Moreno,David R. Nelson,Massimo Colombo,Georgios Papatheodoridis,Juergen K. Rockstroh,Richard Skoien,Eric Lawitz,Ira M. Jacobson +18 more
TL;DR: In this paper, the authors evaluated the impact of non-adherence on sustained virologic response at post-treatment week 12 (SVR12), factors associated with nonadherence, and efficacy in patients interrupting G/P treatment.
9
High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis
Massimo Puoti,Graham R. Foster,Stanley Wang,David Mutimer,Edward Gane,Christophe Moreno,Ting-Tsung Chang,Sam Lee,Rui Tato Marinho,Jean-François Dufour,Stanislas Pol,Christophe Hézode,Stuart C. Gordon,Simone I. Strasser,Paul J. Thuluvath,Ran Liu,Tami Pilot-Matias,Federico J. Mensa +17 more
9